Investment analysts at Evercore ISI have initiated coverage of Upstream Bio (NASDAQ:UPB) with an outperform rating and a price target of $40.00 per share, as detailed in a report published on October 14, 2023. This move signals growing confidence in the biotechnology company’s potential as it develops innovative treatments for inflammatory diseases.
In addition to Evercore ISI, other analysts have recently shared their perspectives on Upstream Bio. On the same day, Truist Financial also began coverage, assigning a buy rating and a target price of $47.00. Conversely, Weiss Ratings reissued a sell (d-) rating on October 8, 2023. Currently, the stock has received a mixed response, with two investment analysts recommending a buy and one suggesting a sell. According to data from MarketBeat, the consensus rating for Upstream Bio stands at hold, with an average target price of $43.50.
Recent Financial Performance
Upstream Bio recently reported its quarterly earnings on November 5, 2023. The company announced an earnings per share (EPS) of ($0.63), surpassing analysts’ expectations of ($0.78) by a margin of $0.15. The total revenue for the quarter reached $0.68 million, slightly above the consensus estimate of $0.65 million. Despite these positive indicators, the company recorded a negative return on equity of 28.71% and an alarming negative net margin of 4,366.77%. Analysts predict that Upstream Bio will report an EPS of (4.3) for the current fiscal year.
Institutional Investment Activity
Recent trading activity reveals that institutional investors are actively adjusting their positions in Upstream Bio. The New York State Common Retirement Fund acquired a new stake in the company worth $29,000 during the first quarter of the year. Additionally, BNP Paribas Financial Markets increased its holdings by 229.8% in the second quarter, bringing its total ownership to 3,097 shares valued at $34,000.
Legal & General Group Plc also expanded its investment by 83.0%, now holding 3,174 shares worth $35,000. CWM LLC boosted its stake by 107.5% in the same quarter, owning 3,312 shares valued at $36,000. Ameritas Investment Partners Inc. similarly increased its position by 95.3%, acquiring 3,558 shares valued at $39,000.
About Upstream Bio
Upstream Bio, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for severe respiratory disorders and other inflammatory diseases. One of its key products is verekitug, a monoclonal antibody targeting the thymic stromal lymphopoietin receptor. The company is also working on therapies aimed at addressing severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
As Upstream Bio continues to navigate the complexities of the biotechnology landscape, analysts and investors alike will be closely monitoring its performance and strategic developments in the coming months.
